Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAME family member 20 (PRAMEF20)
- Target
- PRAMEF20
- Molecular classification
- Other (Leucine-rich repeat protein family), Putative nuclear receptor-interacting protein, Predicted ubiquitin ligase adaptor[2]
01
Overview
PRAME family member 20 (PRAMEF20) is a protein-coding gene in the human genome, located at 1p13.3, and is part of the PRAME gene family—characterized by leucine-rich repeat motifs[2][3]. Like other PRAME family proteins, PRAMEF20 is predicted to function as a nuclear retinoic acid receptor binding protein, potentially acting as a substrate recognition component in Cullin2-type E3 ubiquitin ligase complexes, contributing to regulated protein catabolism; its activity is predicted to be primarily cytoplasmic[2][4]. The PRAME family overall is known for roles in modulating transcriptional responses to retinoic acid, often acting as transcriptional repressors in cancer and development, but there is no specific evidence that PRAMEF20 itself is a therapeutic target or directly involved in particular pathologies[1][3]. No currently known drugs, disease biomarkers, or notable therapeutic safety concerns are associated with PRAMEF20 as of the current knowledge in the literature[2][6].
- Other names
- PRAMEF20PRAMEF21PRAME family member 21OTTHUMG00000007911OTTHUMT00000008157PRAME family member 20/21
02
Biological functions
Nuclear retinoic acid receptor binding[2]Putative substrate recognition in Cullin2-based E3 ubiquitin ligase complex[2]Proteasome-mediated ubiquitin-dependent protein catabolic process[2](By paralogy/inference from the PRAME family) Transcriptional repression and modulation of retinoic acid signaling[1][3]
03
Disease associations
(No strong evidence for PRAMEF20 specifically, but the PRAME family is implicated in) Cancer[1][3]Germ cell development (by homology to other family members)[3]
Beyond the preview
Go deeper on PRAME family member 20 (PRAMEF20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME family member 20 (PRAMEF20).